Advance the Next Frontier of In Vivo Approaches from Research to Clinic
The 4th In Vivo Cell Engineering & Gene Editing Summit, is the only in vivo dedicated event designed to progress cell and gene therapies to the next frontier.
This summit provided attendees with exclusive insights into pioneering IND enabling and clinical data, delivery technologies and effective clinical trial designs. Alongside all of this, our speaker faculty explored regulatory and inter-governmental requirements to accelerate your clinical pipeline.
This year's experts included C-suite executives, VPs and Directors from Myeloid Therapeutics, Ensoma, Capstan Therapeutics, Editas Medicines, AbbVie, Intellia Therapeutics, Umoja BiopharmaΒ and many more!
Biotech and pharma companies are shifting from ex vivo to in vivo therapies due to their improved efficiency, accessibility and cost-effectiveness. With this in mind, this event was a must-attend for those looking to pioneer in this evolving field.
"In vivo genetic medicines are the future, so having a forum for leaders in the field to explore ways to navigate development to meet the needs of patients is very exciting"
Nicolas Boyle, Chief Executive Officer, Abintus Bio
The 2025 World-Class Speaker Faculty Included:
